The rapidly rising costs of cancer care, driven in particular by the high prices of new drugs, are increasingly challenging health-care systems across the world. To ensure accessibility to novel antitumour drugs, novel paradigms are needed at several levels, not only economically, but also in terms of research and new study designs.
- Stefan Sleijfer
- Jaap Verweij
